Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With Fusion-Positive Breast Cancer

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2021 May 26

PMID 34036231

Citations 8

Authors

Satomi Watanabe

Masayuki Takeda

Tomoyuki Otani

Takeshi Yoshida

Kazuko Sakai

Elizabeth Olek

S Michael Rothenberg

Jennifer Kherani

Pearl P French

Kazuto Nishio

Akihiko Ito

Kazuhiko Nakagawa

Affiliations

Soon will be listed here.

Citing Articles

Case report: Eczematous adverse drug reaction after selpercatinib treatment.

Li B, Cao P, Xu W, Zhang L Front Oncol. 2025; 14():1475541.

PMID: 39777333 PMC: 11703860. DOI: 10.3389/fonc.2024.1475541.

Evolution of treatment strategies for solid tumors with RET rearrangement in China and real-world treatment status of Non-small Cell Lung Cancer (NSCLC).

Wang A, Li T, Mao Y, Gao M, Shu S, Xia C BMC Pulm Med. 2024; 24(1):552.

PMID: 39497173 PMC: 11533424. DOI: 10.1186/s12890-024-03371-5.

REThinking the role of the RET oncogene in breast cancer.

Di Grazia G, Conti C, Nucera S, Motta G, Martorana F, Stella S Front Oncol. 2024; 14:1427228.

PMID: 39211557 PMC: 11358597. DOI: 10.3389/fonc.2024.1427228.

-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity.

Desilets A, Repetto M, Yang S, Sherman E, Drilon A Cancers (Basel). 2023; 15(16).

PMID: 37627175 PMC: 10452615. DOI: 10.3390/cancers15164146.

RET signaling in breast cancer therapeutic resistance and metastasis.

Pecar G, Liu S, Hooda J, Atkinson J, Oesterreich S, Lee A Breast Cancer Res. 2023; 25(1):26.

PMID: 36918928 PMC: 10015789. DOI: 10.1186/s13058-023-01622-7.

References

Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S . RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18(3):378-81. DOI: 10.1038/nm.2658. View

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M . Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012; 18(3):382-4. PMC: 3916180. DOI: 10.1038/nm.2673. View

Stransky N, Cerami E, Schalm S, Kim J, Lengauer C . The landscape of kinase fusions in cancer. Nat Commun. 2014; 5:4846. PMC: 4175590. DOI: 10.1038/ncomms5846. View

Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T . KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012; 18(3):375-7. PMC: 6430196. DOI: 10.1038/nm.2644. View

Wirth L, Sherman E, Robinson B, Solomon B, Kang H, Lorch J . Efficacy of Selpercatinib in -Altered Thyroid Cancers. N Engl J Med. 2020; 383(9):825-835. PMC: 10777663. DOI: 10.1056/NEJMoa2005651. View

Schlumberger M, Elisei R, Muller S, Schoffski P, Brose M, Shah M . Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017; 28(11):2813-2819. PMC: 5834040. DOI: 10.1093/annonc/mdx479. View

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M . Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016; 17(12):1653-1660. PMC: 5143197. DOI: 10.1016/S1470-2045(16)30562-9. View

10.

Paratala B, Chung J, Williams C, Yilmazel B, Petrosky W, Williams K . RET rearrangements are actionable alterations in breast cancer. Nat Commun. 2018; 9(1):4821. PMC: 6240119. DOI: 10.1038/s41467-018-07341-4. View

11.

Drilon A, Oxnard G, Tan D, Loong H, Johnson M, Gainor J . Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020; 383(9):813-824. PMC: 7506467. DOI: 10.1056/NEJMoa2005653. View

12.

Bronte G, Andreis D, Bravaccini S, Maltoni R, Cecconetto L, Schirone A . Sorafenib for the treatment of breast cancer. Expert Opin Pharmacother. 2017; 18(6):621-630. DOI: 10.1080/14656566.2017.1309024. View

13.

Allison K, Hammond M, Dowsett M, McKernin S, Carey L, Fitzgibbons P . Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020; 144(5):545-563. DOI: 10.5858/arpa.2019-0904-SA. View

14.

Allred D, Harvey J, Berardo M, Clark G . Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11(2):155-68. View

15.

Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H . The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene. 2014; 34(37):4845-54. PMC: 4468049. DOI: 10.1038/onc.2014.406. View

16.

Miller K, Trigo J, Wheeler C, Barge A, Rowbottom J, Sledge G . A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res. 2005; 11(9):3369-76. DOI: 10.1158/1078-0432.CCR-04-1923. View